UroGen Pharma Management
Management criteria checks 2/4
UroGen Pharma's CEO is Liz Barrett, appointed in Jan 2019, has a tenure of 5.83 years. total yearly compensation is $4.64M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth $3.78M. The average tenure of the management team and the board of directors is 4.3 years and 5.8 years respectively.
Key information
Liz Barrett
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 17.1% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.8% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
Nov 18
UroGen Pharma: There Is Some Potential Here
Aug 28UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Jun 17UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jun 14UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$115m |
| Jun 30 2024 | n/a | n/a | -US$114m |
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$5m | US$794k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$105m |
| Jun 30 2023 | n/a | n/a | -US$109m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$2m | US$764k | -US$110m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | -US$113m |
| Dec 31 2021 | US$4m | US$739k | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$117m |
| Dec 31 2020 | US$2m | US$637k | -US$128m |
| Sep 30 2020 | n/a | n/a | -US$137m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$121m |
| Dec 31 2019 | US$26m | US$695k | -US$105m |
Compensation vs Market: Liz's total compensation ($USD4.64M) is above average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Liz's compensation has increased whilst the company is unprofitable.
CEO
Liz Barrett (62 yo)
5.8yrs
Tenure
US$4,639,589
Compensation
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.8yrs | US$4.64m | 0.77% $ 3.8m | |
| General Counsel | 4.3yrs | US$1.51m | 0.060% $ 291.4k | |
| Chief Medical Officer | 6.9yrs | US$1.36m | 0.34% $ 1.7m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive Vice President of Talent | 1.3yrs | no data | no data | |
| Executive Vice President of Research & Development and Technical Operations | 4.7yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs & Quality | 4.7yrs | no data | no data | |
| Chief Business Officer | 4.2yrs | no data | no data | |
| Senior Vice President of Medical Affairs & Clinical Development | 1.3yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Consultant | 6.3yrs | US$3.86m | no data |
4.3yrs
Average Tenure
56.5yo
Average Age
Experienced Management: URGN's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.8yrs | US$4.64m | 0.77% $ 3.8m | |
| Independent Director | 7.1yrs | US$204.06k | 0% $ 0 | |
| Independent Director | 8.9yrs | US$201.53k | 0% $ 0 | |
| Independent Chairman | 11.9yrs | US$342.18k | 0.97% $ 4.7m | |
| Independent Director | 2yrs | US$192.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | US$313.29k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$194.41k | 0% $ 0 |
5.8yrs
Average Tenure
67yo
Average Age
Experienced Board: URGN's board of directors are considered experienced (5.8 years average tenure).